Eradication of Helicobacter pylori in Hemodialysis Patients

REFERENCES

• Milito G, Taccone-Gallucci M, Brancaleone C, et al. The gastrointestinal tract in uremic patients on long-term hemodialysis. Kidney Int Suppl 1985; 17: 157–160
   Google Scholar
• Ala-Kaila K. Upper gastrointestinal findings in chronic renal failure. Scand J Gastroenterol 1987; 22: 372–376
   PubMed Web of Science ®Google Scholar
• Chalasani N, Cotsonis G, Wilcox CM. Upper gastrointestinal bleeding in patients with chronic renal failure: role of vascular ectasia. Am J Gastroenterol 1996; 91: 2329–2332
   PubMed Web of Science ®Google Scholar
• Chachati A, Godon JP. Effect of hemodialysis on upper gastrointestinal tract pathology in patients with chronic renal failure. Nephrol Dial Transplant 1987; 1: 233–237
   PubMedGoogle Scholar
• Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Dominguez-Munoz E. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004; 19: 617–629
   PubMedGoogle Scholar
• Holtmann G, Howden CW. Review article: management of peptic ulcer bleeding—the roles of proton pump inhibitors and Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19: 66–70
   PubMedGoogle Scholar
• Tamura H, Tokushima H, Murakawa M, et al. Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment. Am J Kidney Dis 1997; 29: 86–90
   PubMedGoogle Scholar
• Satoh K. Indications for Helicobacter pylori eradication therapy and first-line therapy regimen in Japan: recommendation by the Japanese Society for Helicobacter Research. J Gastroenterol 2002; 37: 34–38
   PubMedGoogle Scholar
• Miwa H, Nagahara A, Sato K, et al. Efficacy of one week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. J Gastroenterol Hepatol 1999; 14: 317–321
   PubMedGoogle Scholar
• Miwa H, Ohkura R, Murai T, et al. Effectiveness of omeprazole-amoxicillin-clarithromycin (OAC) therapy for Helicobacter pylori infection in a Japanese population. Helicobacter 1998; 3: 132–138
   PubMedGoogle Scholar
• Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741–746
   PubMed Web of Science ®Google Scholar
• Tsukada K, Miyazaki T, Katoh H, et al. Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in hemodialysis patients. Scand J Gastroenterol 2002; 37: 1265–1268
   PubMed Web of Science ®Google Scholar
• Tamura H, Tokushima H, Murakawa M, et al. Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment. Am J Kidney Dis 1997; 29: 86–90
   PubMedGoogle Scholar
• Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect 1991; 19: 29–37
   PubMed Web of Science ®Google Scholar
• Humbert G, Spyker DA, Fillastre JP, Leroy A. Pharmacokinetics of amoxicillin: Dosage nomogram for patients with impaired renal function. Antimicrob Agents Chemother 1979; 15: 28–33
   PubMed Web of Science ®Google Scholar
• Milito G, Taccone-Gallucci M, Brancaleone C, et al. Assessment of the upper gastrointestinal tract in hemodialysis patients awaiting renal transplantation. Am J Gastroenterol 1983; 78: 328–331
   PubMedGoogle Scholar
• Schlemper RJ, van der Werf SD, Vandenbroucke JP, Biemond I, Lamers CB. Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in The Netherlands and Japan. Scand J Gastroenterol. Suppl 1993; 200: 33–41
   PubMedGoogle Scholar
• Loffeld RJ, Peltenburg HG, Stobberingh E, vd Oever H. Prevalence of Helicobacter pylori antibodies in patients on chronic intermittent hemodialysis. Nephron 1991; 59: 250–253
   PubMedGoogle Scholar
• Jaspersen D, Fassbinder W, Heinkele P, et al. Significantly lower prevalence of Helicobacter pylori in uremic patients than in patients with normal renal function. J Gastroenterol 1995; 30: 585–588
   PubMed Web of Science ®Google Scholar
• Luzza F, Imeneo M, Maletta M, et al. Helicobacter pylori-specific IgG in chronic hemodialysis patients: relationship of hypergastrinemia to positive serology. Nephrol Dial Transplant 1996; 11: 120–124
   PubMedGoogle Scholar
• Abu Farsakh NA, Roweily E, Rababaa M, Butchoun R. Brief report: evaluation of the upper gastrointestinal tract in uraemic patients undergoing hemodialysis. Nephrol Dial Transplant 1996; 11: 847–850
   PubMed Web of Science ®Google Scholar
• Ozgur O, Boyacioglu S, Ozdogan M, Gur G, Telatar H, Haberal M. Helicobacter pylori infection in hemodialysis patients and renal transplant recipients. Nephrol Dial Transplant 1997; 12: 289–291
   PubMed Web of Science ®Google Scholar
• Munoz de Bustillo E, Sanchez Tomero JA, Sanz JC, et al. Eradication and follow-up of Helicobacter pylori infection in hemodialysis patients. Nephron 1998; 79: 55–60
   PubMed Web of Science ®Google Scholar
• Yildiz A, Besisik F, Akkaya V, et al. Helicobacter pylori antibodies in hemodialysis patients and renal transplant recipients. Clin Transplant 1999; 13: 13–16
   PubMedGoogle Scholar
• Huang JJ, Huang CJ, Ruaan MK, Chen KW, Yen TS, Sheu BS. Diagnostic efficacy of (13)C-urea breath test for Helicobacter pylori infection in hemodialysis patients. Am J Kidney Dis 2000; 36: 124–129
   PubMedGoogle Scholar
• Wang YL, Sheu BS, Huang JJ, Yang HB. Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients. Am J Kidney Dis 2001; 38: 98–103
   PubMedGoogle Scholar
• Nakajima F, Sakaguchi M, Amemoto K, et al. Helicobacter pylori in patients receiving long-term dialysis. Am J Nephrol 2002; 22: 468–472
   PubMedGoogle Scholar
• Nakajima F, Sakaguchi M, Oka H, et al. Prevalence of Helicobacter pylori antibodies in long-term dialysis patients. Nephrology (Carlton) 2004; 9: 73–76
   PubMedGoogle Scholar
• Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992; 102: 760–766
   PubMed Web of Science ®Google Scholar
• Gladziwa U, Haase G, Handt S, et al. Prevalence of Helicobacter pylori in patients with chronic renal failure. Nephrol Dial Transport 1993; 8: 301–306
   PubMedGoogle Scholar
• Lieber CS, Lefèvre A. Ammonia as a source of gastric hypoacidity in patients with uremia. J Clin Invest 1959; 38: 1271–1277
   PubMed Web of Science ®Google Scholar
• Giachino G, Sallio-Bruno F, Chiappero F, et al. Helicobacter pylori in patients unfergoing periodic hemodialysis. Minerva Urol Nefrol 1994; 46: 213–215
   PubMedGoogle Scholar
• Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole. Aliment Pharmacol Ther 1999; 13: 719–729
   PubMed Web of Science ®Google Scholar
• Humbert G, Spyker DA, Fillastre JP, Leroy A. Pharmacokinetics of amoxicillin: Dosage nomogram for patients with impaired renal function. Antimicrob Agents Chemother 1979; 15: 28–33
   PubMed Web of Science ®Google Scholar
• Jones RH, Cundy T, Bullock R, et al. Concentrations of amoxicillin in serum and dialysate of uremic patients undergoing peritoneal dialysis. J Infect 1979; 1: 235–242
   Google Scholar
• Miwa H, Murai T, Sato K, et al. Comparison of the efficacy of 400 mg and 800 mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population. J Gastroenterol 2000; 35: 536–539
   PubMedGoogle Scholar